Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. is conducting a Phase III clinical study titled ‘A Randomized, Double-blind, Phase III Clinical Study Comparing the Efficacy and Safety of Cadonilimab Plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX) Versus Placebo Plus SOX as Perioperative Treatment for Patients With Resectable Gastric and Gastroesophageal Junction (G/GEJ) Adenocarcinoma.’ The study aims to evaluate the efficacy and safety of cadonilimab combined with SOX chemotherapy as a perioperative treatment for patients with resectable gastric or gastroesophageal cancer.
The intervention being tested is cadonilimab, an anti-PD-1/CTLA-4 tetrameric bispecific antibody, combined with SOX chemotherapy, which includes oxaliplatin and tegafur-gimeracil-oteracil potassium. This combination is intended to enhance treatment outcomes for gastric and gastroesophageal cancer patients.
The study is designed as a randomized, double-blind, parallel assignment with quadruple masking involving participants, care providers, investigators, and outcomes assessors. The primary purpose of the study is treatment-focused.
The study is not yet recruiting, with a start date set for June 10, 2025. The primary completion and estimated completion dates are not specified, but the last update was submitted on June 10, 2025. These dates are crucial for investors to track the progress and potential market entry of the treatment.
The outcome of this study could significantly impact Akeso’s stock performance and investor sentiment, especially if the results demonstrate a clear advantage over existing treatments. This could position Akeso favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.